Von Willebrand Disease: Gaining a global perspective.


Journal

Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916

Informations de publication

Date de publication:
Jul 2023
Historique:
revised: 02 05 2023
received: 15 02 2023
accepted: 14 05 2023
medline: 21 7 2023
pubmed: 22 5 2023
entrez: 22 5 2023
Statut: ppublish

Résumé

Recent guidelines for von Willebrand Disease (VWD) highlighted the challenges in diagnosis and management. Identifying the number of persons with VWD (PwVWD) internationally will help target support to aid diagnosis of PwVWD. To examine international registration rates of PwVWD, the influence of income status, geographical region and the age and sex profile. Cumulatively, these data will be used to inform future strategy from the World Federation of Haemophilia (WFH) to address unmet clinical and research needs. Data from the 2018/2019 WFH Annual Global Survey (AGS) were analysed, providing a global perspective on VWD registration. Registration rates are lowest in South Asia (0.6/million population) and highest in Europe/Central Asia (50.9/million population, 0.005%), but below the expected prevalence rate (0.1%). National economic status impacted VWD registration rates, reflecting variation in access to optimal healthcare infrastructure. Females represented the majority of PwVWD globally, however, in low-income countries (LIC) males predominated. Age profile varied, with markedly higher rates of paediatric registrations in North America, Middle East and North Africa and South Asia. Rates of type 3 VWD registrations were significantly influenced by economic status (81% of VWD diagnoses in LIC), suggesting only the most severe VWD types are diagnosed in resource limited settings. Significant variation in registration rates of PwVWD exist internationally and is influenced by income status and the presence of HTC networks. Improved understanding of registration rates will enable targeting of advocacy to improve awareness, diagnosis and support for PwVWD internationally. Registration rates of People with Von Willebrand Disease (PwVWD) vary internationally and are influenced by national income status Although females represent the majority of PwVWD globally, in low income countries (LIC) males predominated, possibly related to stigma surrounding gynaecological bleeding. Rates of type 3 VWD registration were significantly influenced by economic status (81% of VWD diagnoses in LIC), suggesting only the most severe VWD types are diagnosed in resource limited settings.

Identifiants

pubmed: 37216656
doi: 10.1111/hae.14804
doi:

Substances chimiques

von Willebrand Factor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1104-1112

Informations de copyright

© 2023 The Authors. Haemophilia published by John Wiley & Sons Ltd.

Références

Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301-325.
James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300.
Lavin M, Aguila S, Dalton N, et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2(14):1784-1791.
Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69(2):454-459.
Bowman M, Hopman WM, Rapson D, et al. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213-216.
Noone D, Skouw-Rasmussen N, Lavin M, et al. Barriers and challenges faced by women with congenital bleeding disorders in Europe: results of a patient survey conducted by the European Haemophilia Consortium. Haemophilia. 2019;25(3):468-474.
van Galen KPM, Lavin M, Skouw-Rasmussen N, et al. Clinical management of woman with bleeding disorders: a survey among European haemophilia treatment centres. Haemophilia. 2020;26(4):1-6.
Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540-546.
Stonebraker JS, Bolton-Maggs PHB, Soucie JM, et al. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010;16(1):20-32.
Stonebraker JS, Bolton-Maggs PHB, Michael Soucie J, et al. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia. 2012;18(3):e91-4.
Lavin M, Aguila S, Schneppenheim S, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130(21):2344-2353.
Atiq F, Saes JL, Punt MC, et al. Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. EClinicalMedicine. 2021;32:100726.
Sidonio RF, Haley KM, Fallaize D. Impact of diagnosis of von Willebrand disease on patient outcomes: analysis of medical insurance claims data. Haemophilia. 2017;23(5):743-749.
Federici AB. Towards a more automatic and rapid laboratory diagnosis of von Willebrand disease. Thromb Res. 2016;141:198-201.
Corrales-Medina FF, Federici AB, Srivastava A, et al. A need to increase von Willebrand disease awareness: vwdtest.com - a global initiative to help address this gap. Blood Rev. 2023;58:101018.
World Federation of Hemophilia. VWD Call to Action.
Stonebraker JS, Bolton-Maggs PHB, Brooker M, et al. The World Federation of Hemophilia annual global survey 1999-2018. Haemophilia. 2020;26(4):591-600.
Bank World, World Bank Country and Lending Groups classification.
World Federation of Hemophilia. Find a haemophilia treatment centre.
Escobar MA, Beijlevelt M, Loney A, et al. World Federation of Hemophilia international hemophilia training fellowship program: 50 years of enhancing global care. Haemophilia. 2022;28(5):S129-S131.
Lavin M, Christopherson P, Grabell J, et al. Longitudinal bleeding assessment in von Willebrand disease utilizing an interim bleeding score. J Thromb Haemost. 2022;20(10):2246-2254.
Weyand AC, James PD. Sexism in the management of bleeding disorders. Res Pract Thromb Haemost. 2021;5(1):51-54.

Auteurs

Jamie M O'Sullivan (JM)

Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences RSCI, Dublin, Ireland.

Ellia Tootoonchian (E)

World Federation of Hemophilia, Montreal, Quebec, Canada.

Baiba Ziemele (B)

World Federation of Hemophilia, Montreal, Quebec, Canada.
Latvia Haemophilia Society, Riga, Latvia.

Michael Makris (M)

Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.

Augusto B Federici (AB)

Department of Oncology and Haematology Oncology, University of Milan, School of Medicine, Milan, Italy.

Claudia Khayat Djambas (C)

Department of Pediatrics, Hotel Dieu de France Hospital Beirut, Saint Joseph University, Beirut, Lebanon.

Magdy El Ekiaby (M)

Hemophilia Treatment Center, Shabrawishi Hospital, Giza, Egypt.

Dawn Rotellini (D)

World Federation of Hemophilia, Montreal, Quebec, Canada.
National Hemophilia Foundation, New York, New York, USA.

Robert F Sidonio (RF)

Aflac Cancer and Blood Disorders, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Alfonso Iorio (A)

Professor and Chair, Department of Health Care Research, Department of Health Research Methods, Evidence, and Impact (HEI), Mike Gent Chair in Healthcare Research, McMaster University, Hamilton, Ontario, Canada.

Donna Coffin (D)

World Federation of Hemophilia, Montreal, Quebec, Canada.

Glenn F Pierce (GF)

World Federation of Hemophilia, Montreal, Quebec, Canada.

Jeffrey Stonebraker (J)

Poole College of Management, North Carolina State University, Raleigh, North Carolina, USA.

Paula D James (PD)

Department of Medicine, Queen's University, Kingston, Ontario, Canada.

Michelle Lavin (M)

Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences RSCI, Dublin, Ireland.
National Coagulation Centre, St. James's Hospital, Dublin, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH